Innovent Biologics Inc (HKEX: 01801), a biopharmaceutical company that develops and commercialises medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, has signed a licensing agreement with Alector Inc (NASDAQ:ALEC), a clinical stage biotechnology company involved in the discovery and development of immune system focused therapeutics, it was reported on Wednesday.
The companies have agreed to develop and commercialise an anti-SIRP-alpha antibody (Alector's project code: AL008) intended for the treatment of oncology indications in China.
The product is Alector's novel antibody targeting the CD47-SIRP-alpha pathway, a potent survival pathway co-opted by tumours to evade the innate immune system. It is claimed to be a first-in-class SIRP-alpha inhibitor with a dual mechanism of action that non-competitively antagonises the CD47-SIRP-alpha pathway by inducing the internalisation and degradation of the inhibitory receptor on macrophages to relieve immune suppression while also engaging Fc gamma to promote immuno-stimulatory pathways that drive anti-tumour immunity.
According to the contract, Innovent will lead the development and commercialisation of the molecule in China, including the manufacturing of the product. Alector will lead development of AL008 outside of China. Financial terms of the contract were not revealed.
Circio unveils circVec proof-of-concept
GSK releases decade-long data on Shingrix efficacy
BiVictriX receives FDA Orphan Drug Designation for AML treatment candidate
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
GSK's meningitis vaccine candidate accepted for FDA review
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
ProAxsis secures GBP1.8m investment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients